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CHAPTER 1 
INTRODUCTION 
1.1 Background:   
Antibiotic resistance is a threat to public health globally.  It is one of the major challenges 
faced by the pharmaceutical industry and medical community today [1].  
According to the European Centers for Disease Control and Prevention (ECDC), every 
year approximately 25,000 people die from the consequences of antibiotic resistance in Europe 
[2]. In the United States, the Centers for Disease Control and Prevention (CDC) has estimated that 
antibiotic-resistant infections make more than 2 million people ill every year, and at least 23,000 
people die from these infections [3].  In addition to the pharmaceutical industry and medical 
community, antibiotic resistance has jeopardized the financial sector as well. Studies have shown 
that an increase in antibiotic resistance has caused a $20 billion increase in healthcare costs in the 
United States, including, a $1.1 billion attributable to unnecessarily prescribed antibiotics [4, 5]. 
Infections caused by antibiotic resistance have increased the length of hospital stays in the United 
States by approximately eight days, thereby increasing the cost of hospitalization. [4].  
These findings strongly indicate the effect of antibiotic resistance on the healthcare system, 
the pharmaceutical industry, and on the financial sector. Thus, the necessity for new antibiotics is 
urgent because of the resistance to many existing and previously effective drugs [1]. Currently, 
however, there are very few new antibiotics in the development pipeline [1]. Therefore, it is 
important to understand the mechanisms and transfer of antibiotic resistance in order to optimize 
our currently available antibiotics. 
 
1.2 Antibiotic resistance:  
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Antibiotic resistance occurs when the targeted microorganism no longer remains 
susceptible to treatment and survives exposure to one or more antibiotics [6-8]. These resistant 
bacteria continue to grow and multiply even in the presence of therapeutic levels of antibiotics and 
thus severely compromise the health of patients [6, 8]. Antibiotic resistance is an increasingly 
serious issue in contemporary medicine worldwide and has emerged as the pre-eminent public 
health concern of this century [8].  
Development of antibiotic resistance is a natural phenomenon [6, 8]. Antibiotic resistance 
can be acquired: a) through mutations (vertical transfer of resistant genes via reproduction) [8, 9], 
and b) via horizontal transfer of resistance (gene exchange among different bacteria) [8, 10, 11]. 
Several mobile genetic elements (MGE’s) play an important role in the latter kind of resistance.  
1.3 Staphylococcus aureus:   
Staphylococcus aureus (S. aureus) is a Gram-positive, coccal bacterium. It is one of the 
five most common causes of nosocomial infections [12].  
S. aureus also occurs as a commensal. Approximately 30-70% of humans are long- term 
carriers of S. aureus [13]. It is found in the anterior nares of the nasal passages and as a part of the 
normal skin flora [14, 15]. Thus, the presence of S. aureus in the human body does not necessarily 
indicate an infection [13].  
 S. aureus infects tissues when the skin or mucosal barrier is breached. It usually affects the 
skin, respiratory tract, soft tissues, bones, and joints [16, 17]. It can cause a plethora of infections, 
from minor skin infections to life-threatening diseases [17].  Minor skin infections include pimples, 
cellulitis, folliculitis, impetigo, furuncles (boils) and carbuncles (a collection of furuncles), 
abscess, and scalded skin syndrome [17]. The life-threatening conditions such as pneumonia, 
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sepsis, meningitis, bacteremia, osteomyelitis, toxic shock syndrome (TSS), and endocarditis can 
also arise due to S. aureus [16, 17].  
1.4 Clinical significance of Staphylococcus aureus: 
The CDC has reported that S. aureus causes around 80,000 infections and 11,000 deaths in 
the United States every year [3]. Another study has also reported that the S. aureus associated Skin 
and Soft Tissue Infections (SSTIs) have increased by 123% in USA over the period of ten years 
(2001-2009) [4]. This study reported an increase of 44% in the cost of hospitalization because of 
S. aureus infections as well. 
Currently, many S. aureus bacteria isolated in the clinical settings have developed partial 
to complete resistance against many antibiotics.  Methicillin Resistant S. aureus (MRSA) is the 
most common type of S. aureus that has become endemic over the past few years [10, 18-20]. 
According to Gould et al, the recent rate of occurrence of MRSA bacteremia is 30-40%, and if  
MRSA is treated with a glycopeptide antibiotic (for example, vancomycin) alone, then this rate of 
bacteremia is as high as it was in the pre-antibiotic era (70-80%) [21].  These statistics explains 
how antibiotic resistance can render an earlier effective drug ineffective.  
Recently, MRSA has developed resistance against vancomycin, the drug of choice to treat 
MRSA infections [1, 5, 22-27]. Three types of S. aureus that show partial or complete resistance 
against vancomycin are, heterogeneous vancomycin- intermediate susceptible Staphylococcus 
aureus (hVISA), vancomycin- intermediate susceptible Staphylococcus aureus (VISA) and high-
level vancomycin-resistant Staphylococcus aureus (VRSA) [25, 27-32]. This is alarming, because, 
these organisms are very difficult to treat with because of their non-responsiveness to vancomycin 
treatment. According to a surveillance study by Richter et al hVISA occurrence increased between 
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2009 and 2011 [33]. VRSA, although rare, has been reported in several parts of the world. The 
United States has had 13 cases of VRSA since 2002 [34].  
 Due to an alarming rate of S. aureus infections and also, due to the continued development 
of resistance against currently employed antibiotics, S. aureus proves to be clinically significant.  
1.5 Development of drug resistance in S. aureus:  
  Various drugs have been employed to date to treat the infections caused by S. aureus. The 
first drug used was penicillin (1943). Penicillin is a β-lactam antibiotic that acts by preventing the 
cross-linking of the peptidoglycan layer, thereby preventing the formation of bacterial cell wall 
[35]. However, by 1950, 40% of the patients were infected with penicillin-resistant S. aureus [36]. 
Penicillin-resistant S. aureus produces β-lactamase enzyme that cleaves the active component of 
penicillin, the β-lactam ring, and renders the drug inactive [37].  
 In response to the emergence of penicillin resistance, semisynthetic antibiotics belonging 
to the class of penicillinase-resistant β-lactam antibiotics were introduced. Methicillin, oxacillin 
and flucloxacillin are a few examples of drugs in this class [38]. In 1959, the first antibiotic in this 
class, methicillin, was introduced. Methicillin acts by inhibiting the penicillin-binding proteins 
(PBP). PBPs are involved in the synthesis of the peptidoglycan layer. By inhibiting PBPs, bacterial 
cell wall synthesis is hampered, and thus bacterial growth is inhibited [39]. After two years of 
clinical use, the first case of methicillin-resistant S. aureus (MRSA) was reported in England [40]. 
Methicillin resistance is conferred by mecA gene that synthesizes an analog of PBP, PBP 2-a, 
having low affinity for methicillin. As a result, PBP remains available for the synthesis of the 
bacterial cell wall and thus the resistance is developed against methicillin [39, 41].  Methicill in 
and oxacillin were still used as a first-line treatment until the 1990s, when the prevalence of MRSA 
became endemic in most hospital settings across the U.S. [23].  
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 After MRSA infections had become endemic, vancomycin became the drug of choice to 
treat S. aureus infections. Vancomycin is a glycopeptide antibiotic which was introduced in 1956 
[6]. In 1997, the presence of VISA, the strains of S. aureus with reduced susceptibility towards 
vancomycin, was reported for the first time [30]. The first case of VRSA, high level Vancomycin-
resistant S. aureus was reported in 2002 in Michigan [34].  Since 2002, 13 cases of VRSA have 
been reported in the U.S. [42]. 
1.6 Characteristics of the S. aureus genome:  
Genetics plays a key role in the development of antibiotic resistance. Therefore, in order 
to understand the development of antibiotic resistance in S. aureus, it is important to understand 
the characteristics of S. aureus genome first.  
The genome of S. aureus consists of a core/stable component which contains all of the 
genes that are essential for the survival of the bacterium and an auxiliary/variable component 
which carries genes that are found in some strains of S. aureus [43-45]. DNA microarray analysis 
has shown that ∼22% of S. aureus genomes consists of variable regions [16, 44, 45].  
The core genome of S. aureus is approximately 2.8 Mb in size. It is highly conserved, and 
it makes up ∼75% of the S. aureus genome. The auxiliary genome of S. aureus accounts for ∼25% 
that is mainly composed MGE’s. MGE’s include plasmids, transposons, chromosomal cassettes, 
bacteriophages, genomic and pathogenicity islands [11, 16, 43, 44, 46].  
1.6.1 Important MGE’s of S. aureus:  
MGE’s, specifically plasmids and transposons play an important role in the transfer of 
vancomycin resistance.  
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 Plasmids are extra-genomic, small circular DNA molecules capable of independent 
replication [45, 47].  They have the ability to integrate with genomic DNA [47]. S. aureus isolates, 
especially hospital associated isolates often carry one or more such plasmids [44]. Based upon the 
virulence genes carried and the size of the plasmid, S. aureus plasmids are classified into three 
types: Type I, II and III. Type I plasmids are smaller in size and are present in multip le copies. 
They usually carry a single virulence gene. Type II plasmids are low copy plasmids and are 15-30 
kb in size. These plasmids carry several virulence genes. Type III plasmids are multi-resis tant 
conjugative plasmids that are > 30 kb in size [11, 43, 45, 46, 48].  
 Transposons or transposable elements are the DNA sequences that are capable of changing 
their positions within a genome [49]. Transpositions occur by creating or reversing mutations [49]. 
Transposons are either smaller in size (and present in multiple copies) or larger in size (and usually 
present in a single copy) [1, 16, 43, 44]. Larger transposons are often found responsible for 
encoding antibiotic resistance genes in S. aureus [43]. Transposons transfer horizontally with the 
help of another MGE like plasmids [48, 50]. Transposons first separate from genomic DNA and 
get inserted into a vector such as a plasmid. Then this assembly gets transferred to a second 
organism where the transposon separates again from the vector plasmid and integrates with 
genomic DNA of the new organism. When the transposons get transferred, they may carry resistant 
determinants with them and thus transfer the drug resistance from one organism to another 
organism [51, 52].  
 Apart from the usefulness in understanding the development of drug resistance, the 
genomic studies are also useful for characterizing various strains of the microorganism.  
1.6.2 Molecular-based typing techniques:  
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The genome of S. aureus can be used for molecular analysis of S. aureus to differentiate 
various strains of S. aureus [53]. Characterization of these strains aids in our understanding of the 
epidemiology of S. aureus and allow us to explore whether specific resistance traits are harbored 
by specific types of S. aureus [54].  
 Various molecular-based typing techniques include pulsed-field gel electrophores is 
(PFGE), multi- locus sequence typing (MLST), spa typing, Staphylococcal cassette chromosome 
typing (SCCmec typing), and coa typing [53].   
PFGE is considered as the ‘gold standard’ in determining different strain types of S. aureus. 
However, its disadvantage is that it is time-consuming, and inter-laboratory comparisons require 
homogenization of protocols [54]. MLST has been successfully applied for strain typing of S. 
aureus; however, it is more costly [54]. spa typing can be used to eliminate the disadvantages of 
PFGE and MLST [55].  
 spa typing is a single locus typing technique, meaning that, it requires the sequence analysis 
of only one gene, the spa gene which encodes S. aureus Protein A. Thus, this technique is more 
economical, faster and more reproducible than the other typing techniques. The spa gene has a 
region ‘X’ that is composed of a variable number of tandem repeats [55]. These repeats are 
assigned a numeric code and then the order of specific repeats is used to elucidate the particular 
spa type [55]. Ridom spa server, Bionumerics, and DNAGear are few examples of software 
programs that are designed for spa typing [56].   
This project focuses on vancomycin resistance in S. aureus. The subsequent sections discuss 
different types of vancomycin resistance in S. aureus. 
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1.7 Vancomycin resistance in S. aureus:  
S. aureus has developed partial (hVISA, VISA) to complete resistance (VRSA) to 
vancomycin. Since vancomycin is a drug of choice to treat MRSA infections, the development of 
vancomycin resistance in S. aureus has become a great concern.  
Mechanism of action of vancomycin: Vancomycin is a glycopeptide antibiotic which acts 
by blocking the bacterial cell wall synthesis. D-Ala-D-Ala residues are an important part of N-
acetylmuramic acid (NAMA) and N-acetylglucosamine (NAGA), which form the backbone of the 
bacterial cell wall. Vancomycin binds with the terminal D-Ala residue and thus prevents cell wall 
formation, thereby preventing the bacterial growth [29].   
1.7.1 hVISA and VISA:  
An intermediate level of resistance against vancomycin is found in hVISA and VISA 
strains [30, 57]. These strains have reduced susceptibility towards vancomycin. VISA strains were 
first observed in Japan in 1997 [30]. They have the MICs of 4-8 μg/ml [57].  
 hVISA can be considered as a pre-VISA stage of vancomycin resistance. These strains are 
susceptible to vancomycin, but, also contain a few vancomycin-resistant subpopulations [57, 58]. 
This heterogeneity arises due to selective pressure resulting from vancomycin exposure. Upon 
continuous exposure to vancomycin, hVISA can convert into a uniform population of VISA [30, 
57].  
Mechanism of intermediate resistance to vancomycin: The reduced susceptibility 
towards vancomycin can occur in two different ways. Firstly, from the changes in the 
peptidoglycan biosynthesis and decreased cross-linking between the peptidoglycan strands. As a 
result of this, more D-Ala-D-Ala residues remain exposed to vancomycin and thus trap 
vancomycin. This bound vancomycin then obstructs the drug molecules from reaching their target 
9 
 
 
 
site [17, 29, 30, 57]. Little is known about the mechanisms behind these alterations in 
peptidoglycan biosynthesis. Another way by which vancomycin susceptibility can be reduced is 
by thickening of the bacterial cell wall, which reduces the ability of vancomycin to diffuse into the 
division septum of the cell [29, 57].  
Clinical significance of hVISA: Patients with hVISA infections show higher rates of 
treatment failure with vancomycin therapy [59]. hVISA stays in the body of patients for a long 
time [25]. Therefore, these patients receive longer course of treatments to eliminate the bacteria 
and thus report longer hospital stays [59]. Because of the longer presence of hVISA, these patients 
have also reported having the higher rates of persistent bacteremia and congestive heart failure 
[58].     
1.7.2 VRSA:  
The strains of S. aureus that are completely resistant to vancomycin, are known as VRSA 
(MICs ≥ 16 μg/ml) [29]. Treating VRSA infections is very difficult as VRSA is resistant to almost 
all of the commonly employed antibiotics. Therefore, the emergence of VRSA is considered to be 
a big threat. Since 2002, thirteen cases of VRSA have been reported in the United States [42]. 
Apart from the United States, VRSA is also reported in India, Pakistan, Iran and Brazil [60-62].  
Mechanism of complete resistance to vancomycin: In S. aureus, vancomycin resistance 
is acquired from the conjugal transfer of the vanA gene from Vancomycin-resistant E. faecalis 
(VRE) [27, 32, 42]. In VRSA, vanA gene causes an alteration of the terminal peptide to ‘D-Ala-
D-Lac’ in place of D-Ala-D-Ala that has reduced affinity towards vancomycin. As a result, 
vancomycin cannot bind with the terminal D-Ala residue and thus allows the cell wall formation 
[29].  
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The conjugal transfer of vanA gene from VRE to S. aureus is the key step in the 
development of VRSA. The mechanism of this transfer is explained next.  
Earlier studies have shown that VRSA has emerged through the transfer of a vancomycin 
resistance determinant gene, vanA, from VRE to S. aureus [27, 32, 42, 52, 63]. The Inc-18 like 
plasmid present in VRE, carries the vanA gene on a transposon, Tn1546 [27, 63]. This Inc-18 like 
plasmid is then transferred from VRE to S. aureus only in the presence of pSK41 plasmid in S. 
aureus [52] (Figure 1).  
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Figure 1-Mechanism of the transfer of vancomycin resistance from VRE to S. aureus: The 
mechanism of transfer of vancomycin resistance from VRE to S. aureus is depicted in Figure 1. 
VRE containing the vanA gene (associated with Tn1546) on an Inc-18 like plasmid (A) acts as a 
donor cell and a S. aureus containing the pSK41 plasmid (B) acts as a recipient cell. The 
vancomycin resistance is transferred via conjugative transfer of the Inc-18 like plasmid to S. 
aureus. This transfer is facilitated by the presence of the pSK41 plasmid. Post conjugation, VRE 
with the Inc-18 like plasmid (C) and S. aureus containing pSK41, as well as the Inc18 like plasmid 
carrying vanA gene, are obtained. The Inc-18 like plasmid in S. aureus is lost during replication, 
but, it survives enough for Tn1546 carrying the vanA gene to transfer to the genome of S. aureus 
or pSK41.  
(This figure is adapted from the mechanism of vancomycin resistance transfer as published 
previously [27, 52, 64])  
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pSK41-like plasmids are multi-resistant, low copy, conjugative plasmids of S. aureus 
[65]. Plasmids belonging to this family include pSK41, pGO1and pJE1 [66]. These plasmids are 
known to confer resistance against aminoglycoside antibiotics like gentamycin, kanamycin, and 
tobramycin via aadD and aacA-aphD genes [65-67].  
The pSK41 plasmid is 46.4 kb in size [65]. Genetically, it consists of a highly conserved 
backbone (which contains sequences for replication, conjugative transfer and maintenance), 
transposon-like structures, and co-integrated plasmids flanked by IS257 (that contain resistance 
determinants) [65]. IS257 divides the backbone of pSK41 into two regions, the tra region (which 
contains genes that regulate conjugative transfer of the plasmid) and region 1 (which contains 
genes involved in replication, partitioning and multimer resolution) [65].  
Inc-18 like plasmids carried by Enterococci have an ability to transfer a transposon 
encoding vanA (Tn1546) to S. aureus [51]. However, this transfer appears to be rare, possibly 
because of robust barriers like S. aureus endonuclease, which block this transfer [44].  
All thirteen VRSA cases of the United States and their associated VRE and MRSA isolates 
have been characterized for the presence of Inc-18 like plasmid and pSK41 [42]. Nine (four MRSA 
and five VRSA) isolates representing seven VRSA cases were found to contain marker genes that 
indicate the presence of pSK41. In two cases, pSK41 was found in VRSA as well as in associated 
MRSA isolates, whereas, in the remaining five cases, pSK41 was found to be present in either the 
actual VRSA isolate or in an associated MRSA isolate. In the case of Inc-18 like plasmid, eight 
associated VRE isolates carried Inc-18 like plasmid [42].  This information was used to confirm 
the mechanism of transfer of vanA gene from VRE to S. aureus. 
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CHAPTER 2 
RATIONALE AND SPECIFIC AIMS 
2.1 Rationale: 
  As mentioned earlier, vancomycin is currently the first-line treatment to treat MRSA 
infections. Therefore, the emergence of VRSA is a severe health care threat, as there are limited 
antibiotics that are available to effectively treat patients, who are infected with this pathogen [1]. 
 In order to evaluate the potential threat of emergence of VRSA, we specifically aimed to 
determine the prevalence of the pSK41 plasmid, which plays an important role in the transfer of 
vancomycin resistance from VRE to S. aureus. 
The importance of hVISA: VRSA emerges as a result of vancomycin resistance gene 
(vanA) transfer from VRE to S. aureus. For this transfer, it is required that the patient has a VRE 
and S. aureus co-colonized in his body. Thus, this co-colonization of VRE and S. aureus in a 
patient can be considered the first step towards the possible transfer of vancomycin resistance. A 
patient’s likelihood of acquiring VRE is directly associated with hospital admission. hVISA has 
reported longer treatment courses and thus longer hospital stays, increasing the time during which 
the patient is at risk of VRE infection. Therefore, hVISA persistence in the body along with 
frequent and longer hospitalization, increase the chances of VRE co-infection in hVISA infected 
patients compared to non-hVISA infected patients.  
The importance of the pSK41 plasmid: The pSK41 plasmid mediates the transfer of vanA 
from VRE to S. aureus. In the absence of pSK41, this transfer is unlikely to take place. Thus, this 
plasmid is very important to evaluate the emergence of VRSA. Plus, if hVISA carries the pSK41 
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plasmid, the risk of the VRSA emergence is increased because of the higher chances of co-
colonization of VRE and S. aureus in hVISA.   
2.2 Specific Aims:  
1. A) To determine the prevalence of pSK41 in all hVISA and non-hVISA isolates. 
      B) To compare the prevalence of pSK41 in hVISA isolates against matched non-    
           hVISA isolates.                                                        
2. To compare the prevalence of pSK41 by patient severity in hVISA isolates. 
3. To compare the strain types between hVISA and non-hVISA isolates and between pSK41-
positive and pSK41-negative isolates by spa typing. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Samples:  
The samples were collected from patients presenting for care in Michigan, New York, 
Pennsylvania and Ohio. The patients included in the study were adults aged ≥ 18 years, who had 
blood cultures positive for MRSA with vancomycin MIC ≤ 2µg/ml, and had received vancomycin 
for ≥ 72 hours. All the isolates were confirmed to be hVISA by Population Analysis Profiling 
(PAP).  In order to compare hVISA isolates to non-hVISA isolates, non-hVISA isolates were 
identified and matched to hVISA surveillance isolates when possible, based on age, source of 
infection, and year of infection, in a nested matched cohort design.  
           3.1.2 Controls:  
               A S. aureus isolate from a previous study [68], which was known to contain pSK41 and 
gave reproducible results, was used as a positive control in this project. A positive control was 
included at every step to confirm the success of that step. Molecular-grade water was used as a 
negative control to confirm the absence of contamination at any step.  
3.2 Methods 
3.2.1 Bacterial Growth:  
All the organisms were first grown on tryptic soy agar (TSA) plates. After an incubation 
of 18-24 hours, at 370C, one colony was selected, and further grown in Muller Hinton broth 
(MHB), (5ml for genomic DNA extraction and 10 ml for plasmid DNA extraction) for 18-24 hours 
at 370C.  
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3.2.2 DNA Extraction: 
       3.2.2.1 Total DNA Extraction 
Total DNA was extracted from all the isolates by using Wizard® SV Genomic DNA 
Purification Kit (Promega). This kit is used to extract the total bacterial DNA (genomic DNA, as 
well as accessory DNA). Bacterial cultures were grown overnight, centrifuged, and cell pellets 
were re-suspended in PBS. Bacterial lysates were then prepared by adding Wizard SV lysis buffer. 
Bacterial lysates were later transferred to Wizard SV mini-columns for vacuum purification and 
washed with column wash solution, four times. Total DNA was eluted using nuclease-free water. 
DNA was stored at -700C until further testing was performed. This DNA was further used to 
determine the spa type (See Section 3.2.5).  
3.2.2.2 Plasmid Purification  
      Plasmid DNA was extracted from all the samples using PureYield™ Plasmid Miniprep 
System (Promega). Bacterial cultures were grown overnight, centrifuged, and cell pellet were re-
suspended in TE buffer. Bacterial lysates were prepared by adding cell lysis solution followed by 
a cold neutralization solution. Lysates were thoroughly mixed in between addition of these 
reagents. Later, the lysates were centrifuged, and further purified using a vacuum manifold. DNA 
was eluted using nuclease-free water and stored at -700C until further testing was performed.  
3.2.3 PCR Assays:  
Polymerase Chain Reaction (PCR) was used for the amplification of target genes used to determine 
the presence of pSK41. Two sets of pSK41 specific primers were used [59, 69]. Primer set I [69] 
was used as a preliminary screen, to detect how many samples possibly carry pSK41. The actual 
number of samples carrying pSK41 was then confirmed by performing another PCR using primer 
set II [59]. Two primer sets were used because of the problem of inconsistent and non- reproducible 
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detection of pSK41 by Primer set I. Detection of pSK41 using Primer set II was found to be 
reproducible.  
3.2.3.1 Preliminary Screening for pSK41 plasmid 
Previously published primers were used for preliminary screening for the presence of 
pSK41 marker genes [69]. These primers have been designed to target the following regions of 
pSK41: pre, nes, traG, traK, traL, traE and traM. pSK41 was identified using these specific 
marker genes. 50µl of PCR reaction mixture was set up using 17µl of distilled water, 1.5µl each 
of 10 µM forward and reverse primers, 5µl of extracted DNA solution and 25µl of PCR Master 
Mix 2X (Promega). DNA amplification was carried out using T100 Thermal Cycler (Bio-Rad). 
PCR conditions were an initial denaturation at 95 °C for 2 min; 30 cycles of 95 °C for 1 min, 52–
56 °C for 1 min and 72 °C for 1 min and a final elongation at 72 °C for 5 min [69].  
3.2.3.2 Confirmation of pSK41 plasmid 
A second set of previously published primers was used to confirm the presence of pSK41 
[59]. These primers have been designed to target the following regions of pSK41: traE, traI, repA. 
The PCR reagent volumes were as described earlier. Thermal cycling parameters included an 
initial denaturation at 95°C for 15 min; 35 cycles of 94°C for 30 s, 58°C for 90 s, and 72°C for 90 
s; and a final extension at 72°C for 10 min [59].  
3.2.4 Gel Electrophoresis:  
The presence of amplified marker genes was determined by performing gel electrophores is. 
Agarose gel (3%) was casted; ethidium bromide was added to help DNA visualization and 
amplified DNA mixed with loading dye was loaded onto the gel along with an appropriate DNA 
ladder. Gel electrophoresis was carried out at 3Volts/cm for 45 min. The bands of DNA referring 
to these specific genes were observed under UV light. For the last few experiments, ethidium 
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bromide-UV illumination was replaced by the Sybr Safe- Embi Tec PrepOne™ Sapphire gel 
electrophoresis system that uses LED illumination. This illumination prevents DNA damage 
during electrophoresis. A selection of samples was retested to confirm that this new method of 
detection did not affect the detection of pSK41. The results produced by LED illumination gel-
electrophoresis were no different from UV illumination gel electrophoresis.  
            3.2.5 spa typing:  
Strain types of these isolates were determined by spa typing. Previously published primers 
were used to carry out PCR [70]. These primers have been specifically designed to amplify a 
variable region of the spa gene. The PCR reaction was set up, in the same way, as described above. 
The temperature profile included an initial denaturation for 10 min at 95°C; 30 cycles of 30 s at 
95°C, 30 s at 60°C, and 45 s at 72°C; and a final extension at 72°C for 10 min [70]. PCR products 
were purified using Wizard® SV 96 PCR Clean-Up System by Promega. After that, DNA was 
sequenced by Sanger sequencing technique at the Applied Genomic Technology Center (AGTC) 
of Wayne State University.  DNA sequences were then analyzed to determine the spa types using 
the Sequencher program and DNA Gear software [55].  
            3.2.6 Statistical Analysis: 
The prevalence of pSK41 in hVISA isolates was calculated and compared to the prevalence 
of pSK41 in non-hVISA isolates. The prevalence of pSK41 was compared in patients with high 
severity (requiring ICU admission) to pSK41 prevalence in patients with low severity (not 
requiring ICU admission). These comparisons were used to analyze the association of pSK41 with 
hVISA/Non-hVISA and patient severity. All the comparative studies were done using Fisher’s 
exact test; except for the comparison of prevalence of pSK41 within matched pairs, which was 
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performed by McNemar’s test for matched data. Graphpad and SPSS were used to perform all 
statistical analyses.  
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CHAPTER 4 
RESULTS  
A total of 144 samples were collected from patients presenting for care of bloodstream 
infections or infective endocarditis in Michigan, New York, Pennsylvania and Ohio. Out of these 
144 patients, 84 patients had infection due to hVISA, and 60 patients had infection due to non-
hVISA. The study group chosen for this project was subdivided into a matched cohort (60 hVISA 
patients matched with 60 non-hVISA patients based upon age, source of infection and year of 
infection) and a surveillance cohort (24 hVISA patients, unmatched). Baseline demographics and 
clinical outcomes of all hVISA and non-hVISA patients with available clinical data are presented 
in Table 1.  
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Table 1: Baseline demographics and clinical outcomes of hVISA and non-hVISA patients. 
Feature hVISA (n=73)* Non-hVISA (n=60) 
Basic Demographics 
BMI (Median, IQR) 24.93 (21.27-28.67) 25.31 (21.79-29.44) 
Female Sex 32 (43.8%) 21 (35%) 
APACHEII Score 
(Median, IQR) 
12 (8-18) 10 (6.25-15) 
Charlson Index (Median, 
IQR) 
3 (1-4) 2 (1-4) 
ICU Ever 29/61 (39.7%) 23 (38.3%) 
Previous Hospitalization 41 (56.1%) 33 (55%) 
Nursing Home 
Admission 
5/61 (8.2%) 6 (10%) 
Previous Surgery 4 (6.5%) 10 (16.6%) 
Previous Antibiotics 33/61 (45.2%) 24 (40%) 
Prior Staph Infection 9 (14.8)  8 (13.1) 
Renal Disease 28/61(45.9%) 26 (43.3%) 
Hemodialysis 17 (27.9%)  10 (16.4) 
Diabetes 20/61 (32.7%) 16 (26.6%) 
Decubitus Ulcer 11 (15%) 3 (5%) 
Prosthetic                              4/62 (6.4%)                                4 (6.6%) 
Clinical Outcomes 
Deaths at Discharge 14 (22.9%) 6 (10%) 
Status after 30 days 
(Deaths) 
15 (20.5%) 7 (11.6%) 
(*: Patient data for 11 hVISA infected patients could not be obtained through previous records) 
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Specific Aim: 1. A) To determine the prevalence of pSK41 in all hVISA and non-hVISA 
isolates. 
4.1 Detection of pSK41:  
All 144 samples were tested for the presence of marker genes for the plasmid, pSK41. 
Detection of pSK41 was carried out by a two-step screening. Two different assays were required 
due to inconsistent gene detection in the first PCR assay.  
4.1.1 Preliminary screening to detect pSK41:  
Preliminary screening for the detection of pSK41 was performed by using primer set I [69]. 
pSK41 genes targeted by this primer set were: pre, nes, traG, traK, traE, traL, and traM. Two 
problems were found while working with these primers: (A) False positive detection using the 
‘pre’ gene primer and (B) Inconsistent and non-reproducible detection of genes, leading to 
questionable determinations of pSK41-positive samples.  
These two problems are described further.  
(A) False positive data for the ‘pre’ gene assay: 
The ‘pre’ gene was one of the pSK41 marker genes from the primer set I. Upon DNA 
amplification, 77.7 % of the samples (112/144) had bands representing the presence of the ‘pre’ 
gene. As it was the only gene observed in most of the samples, the specificity of this marker gene 
became questionable, as compared to the other reports [29]. An example of gel electrophores is 
result showing false positive detection of ‘pre’ gene is shown in Figure 2. 
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. 
In order to confirm the non-specificity of this ‘pre’ primer with pSK41, the sequences of 
the amplicon from study samples were compared to the other available sequences to see a possible 
match between the sequence of ‘pre’ gene and other sequences of the S. aureus genome. This 
comparison was performed using the BLAST tool by NCBI (http://blast.ncbi.nlm.nih.gov/). The 
results showed that 106 sequences from the S. aureus genome had a sequence similar to the 
sequence of ‘pre’ gene.  These similar sequences were found to be present in different MGEs of 
S. aureus (like pUB110 and SCCmec), as well as a part of the genome of S. aureus. Because of 
these similarities, most of the samples showed an amplification with the ‘pre’ gene primer, 
however, the pSK41-specific ‘pre’ gene was not necessarily getting amplified in every sample, 
therefore, giving a false positive data. The previous study using these primers did not report this 
non-specificity issue of the ‘pre’ gene assay [69]. The results of BLAST are shown in Figure 3.  
Figure 2-False positive data for the ‘pre’  gene assay: Five samples, #3762, #3775, 
#3782, #3783, and #3817, were tested for the presence of pSK41 using primer set I. Out of 
the five genes tested for each sample, only the ‘pre’  gene had amplification in all five 
samples. The bands observed for the ‘pre’  gene are highlighted in the picture. 
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(B) Inconsistent and non-reproducible detection of genes:  
Inconsistent detection: A detection was called as an ‘inconsistent’ detection, when, all 
seven marker genes did not amplify. Inconsistent detections gave amplifications for a variable 
number of marker genes, thus, complicating the detection of pSK41 (Figure 4). The previous study 
using these primers have considered the isolate to be pSK41-positive if an amplification was 
observed for any of the marker genes [69]. With that definition of positive detection, we got 
misleading positive data for our samples. 
Figure 3-BLAST hits matching to the sequence of ‘pre’ gene: Distribution of 106 
BLAST hits is shown in this figure. Red colored bands indicate an alignment of ≥ 200bp and 
the pink colored bands indicate an alignment of 90-200bp. One red band represents the 
sequence of ‘pre’ gene from pSK41. Similarly, two other bands show  similar sequences 
from pGO1 and SCCmec Other commonly found sequences of S. aureus, having a similar 
sequence like the ‘pre’  gene are shown by other red bands in this figure. 
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Non-reproducible results: The results were called ‘non-reproducible’, when the same 
sample produced different results in different independent PCR runs. For example, if sample ‘A’ 
gave an amplification for three genes in its first PCR run, it did not amplify the same three genes 
in its second PCR run or in other words it did not reproduce the same result in its second run 
(Figure 5).  
 
Figure 4-Inconsistent detection of genes: Inconsistent gene detection in primer set I is 
shown in this figure. Isolate #3044 had amplification of 4/7 genes while in #3827, 3875, 
4932, 5583 only one gene showed amplification. Only #5582 showed amplification for 
6/7 genes. This variation in the number of genes detected was observed in all the 
samples. 
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RUN 1                                                              RUN 2 
 
To check whether this inconsistency in detection was dependent on a particular colony 
chosen for an experiment, a five-colony experiment was run as well. In this experiment, five 
colonies of the same sample from the same agar plate were randomly chosen and simultaneous ly 
tested for the presence of pSK41. The detection of pSK41 was found to be consistent amongst all 
chosen colonies (Figure 6). Therefore, it was confirmed that the detection of pSK41 genes did not 
depend on the colony chosen.  
Figure 5-Non-reproducible detection amongst duplicate runs: Two samples, 
#3044 and #3817 were independently tested two times (Independent culturing, DNA 
extraction, PCR and gel electrophoresis). In the first run, #3044 showed 
amplification for six genes and #3817 amplified for 3 genes. To check if #3817 and 
other samples from the same batch produce better results, the whole batch was 
retested. However, in the second run, #3044 amplified for only 3 genes and #3817 
amplified for only one gene. Such inconsistency between independent runs was 
observed throughout. Thus, the results with these primers were found to be non-
reproducible. 
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                          3044 (1)                                3044 (2)                          3044 (3) 
 
 
 
 
  
4.1.2 Confirmation of pSK41 by another primer set: 
Due to an unreliable detection of pSK41 by primer set I, the extracted plasmids from all 
the samples were tested by a second, previously published set of primers, primer set II [59]. These 
were three primers, traE, traI, and repA. Detection of pSK41 was found to be reproducible and 
reliable with this primer set (Figure 7).  
 
  
Figure 6-Consistency of results amongst various colonies from the same 
sample: Amplification of pSK41 primers from three (out of five) colonies of the 
sample #3044 is depicted here. Six marker genes got amplified in each colony. 
One gene did not amplify in any of the colony. Such consistency was observed 
with other samples as well, confirming that the results did not vary based upon 
the colony chosen. 
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10 samples were found to carry the pSK41 plasmid by primer set II [59]. The marker genes 
observed in these pSK41-positive isolates are summarized in Table 2.  
 
 
 
 
 
 
 
 
Figure 7-Confirmation of pSK41-positive isolates by primer set II: Detection of 
pSK41 by primer set II is shown in this figure. #3875 and #4932 showed bands for one 
or two genes and in #3044, #5582, #5253 and #4941 amplification of all three genes 
was observed. 
#3044 #3875 #4941 #5253 #5582 #4932 
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Table 2: The marker genes observed in pSK41-positive samples 
hVISA/Non-hVISA SAMPLE # PRIMER SET II [59] 
traE traI repA 
hVISA 3044 + + + 
Non-hVISA 4941 + + + 
hVISA 5582 + + + 
hVISA 5747 + + + 
hVISA 3829 + + + 
hVISA 5992 + + + 
hVISA 5253 + + + 
Non-hVISA 3606 + + + 
hVISA 3875 + - + 
hVISA 4932 + - + 
 
Specific Aim: 1.B) To compare the prevalence of pSK41 in hVISA isolates against matched 
non-hVISA isolates.                                                        
4.2 Calculation of the prevalence of pSK41 
Ten samples out of 144 samples were found to carry pSK41. The prevalence of pSK41-
positive isolates was calculated in overall study group, in hVISA isolates (unmatched), in hVISA 
isolates (matched) and in non-hVISA isolates (matched) (Table 3).  
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Table 3: Prevalence of pSK41 in various study groups 
Study Group      Prevalence of pSK41 
hVISA from a surveillance study              2/24 (8.3%) 
hVISA from a matched study 6/60 (10%) 
Non-hVISA from a matched study 2/60 (3.3%) 
Overall Prevalence of pSK41 10/144 (6.9%) 
 
4.2.1 A comparison of the prevalence of pSK41 in hVISA isolates against non-hVISA isolates: 
The pSK41 plasmid was three times more commonly found in hVISA isolates (6/60, 10%) 
than in non-hVISA isolates (2/60, 3.33%). However, by McNemar's test for matched data, results 
were not statistically significant. In the whole study group, the prevalence of pSK41 was found to 
be more in hVISA isolates (9.5%) as compared to non-hVISA isolates (3.3%). 
4.2.2 The prevalence of pSK41 in all hVISA isolates compared to non-hVISA isolates:  
To calculate the overall prevalence of pSK41 amongst hVISA and non-hVISA patients, all 
144 samples were considered. This analysis did not control for heterogeneity of patient 
characteristics including age, source of infection and the year of infection. A comparison of the 
overall prevalence of pSK41 in all hVISA (n=84) and non-hVISA (n=60) is shown in Table 4. The 
overall prevalence of pSK41, in the whole study group, was found to be 6.9%. In hVISA isolates, 
this prevalence was found to be 5.5% whereas in non-hVISA, only 1.3% prevalence was reported. 
The association between hVISA status and the plasmid, pSK41, was not statistically significant (p 
= 0.20, Fischer’s exact test).  
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Table 4: The prevalence of pSK41 in all the hVISA isolates compared to non-hVISA 
isolates. 
 pSK41-positive pSK41-negative Total 
hVISA 8 (5.5%) 76 (52.7%) 84 (58.3%) 
Non-hVISA 2 (1.3%) 58 (40.2%) 60 (41.6%) 
Total 10 (6.9%) 134 (93.1%) 144 
 
4.2.3 The prevalence of pSK41 in hVISA isolates compared to matched non-hVISA 
isolates:  
To determine if controlling for patient characteristics affected our results, a second analysis 
was performed. Only the samples from matched study were chosen to compare the prevalence of 
pSK41. A pair-wise comparison was performed to know if the prevalence of pSK41 was associated 
with hVISA/non-hVISA.  
Table 5 shows the prevalence of pSK41 in hVISA isolates compared to matched non-
hVISA isolates. The association between heterogeneity in vancomycin resistance and the presence 
of pSK41 was statistically non-significant. (p = 0.29, McNemar's test for matched data). 
Table 5: The prevalence of pSK41 in hVISA compared to matched non-hVISA isolates. 
 Non-hVISA 
 
 
hVISA 
 pSK41-positive pSK41-negative Total 
pSK41-positive 0 (0%) 6 (10%) 6 (10%) 
pSK41-negative 2 (3.3%) 52 (86.6%) 54 (90%) 
Total 2 (3.3%) 58 (96.6%) 60 
32 
 
 
 
4.3 Specific Aim: 2: To compare the prevalence of pSK41 in hVISA isolates by the patient 
severity:  
hVISA infected patients admitted to the ICU were compared with hVISA infected patients 
admitted to the general inpatient ward. Results showed that there were only two patients who were 
admitted to the ICU and detected with pSK41 in the hVISA group. The other four patients with 
pSK41 detected were not admitted to ICU. This data is shown in Table 6. The association between 
patient severity and the presence of the pSK41 plasmid was not statistically significant (p = 0.99, 
Fisher’s exact test). 
Table 6: Comparison of the prevalence of pSK41 in hVISA isolates by the patient severity. 
 ICU Non-ICU Total 
pSK41-positive 2 (3.2%) 4 (6.4%) 6 (9.6%) 
pSK41-negative 15 (24.5%) 40 (65.5%) 55 (90.1%) 
Total 17 (27.8%) 44 (72.1%) 61 
 
4.4 Specific Aim 3:  To compare the strain types between hVISA isolates and non-hVISA 
isolates and between pSK41-positive and pSK41-negative isolates by spa typing:  
4.4.1 Results for spa PCR: 
Detection of the spa gene was found to be consistent. Figure 8 shows the gel picture of spa 
detection. The spa bands from different samples were observed at different lengths. This happens 
as a result of a variable size of the gene that is amplified during PCR. spa primers are designed for 
the amplification of a variable region, region X, within the ‘spa’ protein. Because of mutations, 
this region X has a variable number of tandem repeats (VNTR). VNTR give rise to spa genes of 
variable sizes and thus these are observed at different lengths on gel [55, 71].  
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4.4.2 Distribution of strain types: 
 Amongst 144 hVISA and non-hVISA samples, the spa types t002 (n= 36, 25%) and t008 
(n=35, 24.3%) were most commonly found. Seventeen (11.8%) isolates could not be typed. Other 
common spa types were t004 (n=7, 4.8%), t062 (n=8, 5.5%) and t688 (n=5, 3.4%). pSK41 plasmid 
was found to be present in multiple spa types. (Table 7).  
 
 
 
 
 
Figure 8-Bands of spa gene after amplification: Bands for spa genes after amplification, are shown in 
this figure. 
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Table 7: Distribution of the strain types between hVISA and non-hVISA isolates and 
between pSK41-positive and pSK41-negative isolates by spa typing. 
Category t002 t008 t004 t062 t688 Other 
types 
Unknown 
type 
hVISA 21 21 7 8 2 20 5 
Non-hVISA 15 14 0 0 3 16 12 
pSK41-positive 1 2 2 2 0 1 2 
pSK41-negative 35 33 5 6 5 35 15 
 
hVISA status (hVISA/non-hVISA), spa type and patient severity of pSK41-positive 
isolates is summarized below (Table 8).  
Table 8: Summary of pSK41-positive isolates 
Isolate # hVISA/Non-hVISA spa type Patient severity 
3044 hVISA t062 ICU 
3606 Non- hVISA t008 ICU 
3875 hVISA t004 Non-ICU 
4932 hVISA t004 Non-ICU 
4941 Non- hVISA Unknown ICU 
5253 hVISA t008 ICU 
5582 hVISA t002 Non-ICU 
5747 hVISA t3234 Non-ICU 
3829 hVISA t062 Missing 
5992 hVISA Unknown Missing 
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CHAPTER 5 
DISCUSSION  
 This study included 144 samples, of which 84 were hVISA, and 60 were non-hVISA. 120 
of the samples were collected from a matched study (60 hVISA samples matched to 60 non-hVISA 
samples), and 24 hVISA samples could not be matched.  All isolates were tested for the presence 
of pSK41. Ten of 144 samples were found to contain pSK41. Eight of these pSK41-positive 
samples were hVISA, and the remaining two were non-hVISA.  
In a previous study based on these patients, the odds of vancomycin treatment failure were 
found to be 11 times greater for patients with hVISA infection than for patients with non-hVISA 
infection [58]. Due to the patterns of persistent and recurrent hVISA infections, vancomycin 
therapy has shown greater failure rates in hVISA patients than in non-hVISA patients.  
Vancomycin treatment failure in hVISA patients was found to be associated with bacteremia, 
recurrence of MRSA-blood stream infections and change or addition of antibiotic against MRSA 
[58]. All patients had MRSA-blood stream infections, infective endocarditis, or bacteremia. 
Furthermore, the patients with hVISA infections reported longer hospital stays than the patients 
with non-hVISA infections [58], thus, they had a higher risk of VRE exposure.  
 It was also observed that few common underlying characteristics of the hVISA patients of 
this study were similar to those found in thirteen VRSA patients of the United States (discussed in 
Section 1.7.2) [58, 60] including renal disease (45.9%), diabetes (32.7%) and hemodialysis (23%) 
[58, 60].  
Therefore, we can say that few of the hVISA patients in our study had more than one risk  
factors (Underlying conditions similar to known VRSA patients, persistent and frequent 
hospitalization, and the presence of pSK41) to develop VRSA infection.  
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Detection of pSK41 in hVISA and non-hVISA isolates: The pSK41 plasmid was 
detected by two sets of previously published primers [59, 69]. Primer set I (pre, nes, traG, traK, 
traL, traE and traM) [69] was used as the first marker set of pSK41. A previous study using this 
primer set did not report any non-specificity issues with the assay of the ‘pre’ gene [69]. However, 
we found that the primer sequence for the ‘pre’ gene was not uniquely associated with pSK41. The 
primer sequence was found to be similar to 106 other sequences belonging to the genome of S. 
aureus. Hence, we confirmed that the ‘pre’ gene assay cannot be used as a reliable marker for 
pSK41 because of these similarities with non-pSK41 sequences.  
Another problem with this primer set was the inconsistent and non-reproducible detection 
of pSK41.  We were unable to determine the reason for the inconsistent detection of pSK41 using 
this primer. However, this inconsistency was reported in the previous study as well [69]. The 
previous study considered the isolate to be pSK41-positive if it amplified any of the marker genes 
[69]. Based upon this consideration, we found that most of our samples (77.7%) would be falsely 
detected as pSK41-positive by the ‘pre’ gene assay alone. Therefore, this consideration did not 
work in our study.  
We also addressed the problem of non-reproducibility of primer set I. We performed an 
experiment in which one batch of samples was independently run twice. The results from 
independent duplicate runs were not reproduced, which indicates that the assay lacked 
reproducibility of the results.   
Lastly, we conducted a five-colony experiment to check if the inconsistency of plasmid 
detection was dependent on the particular colony chosen for the experiment. However, when five 
different colonies from the same sample were run simultaneously, the assay produced consistent 
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results. Hence, we can confirm that the presence of pSK41 does not depend on the colony chosen 
for the experiment. 
We were able to demonstrate reproducible detection of pSK41 using the second set of 
primers (traE, traI, and repA) [59]. Ten samples were found to carry the pSK41 plasmid. We found 
that, out of the ten samples that carried pSK41, eight samples amplified all three pSK41 marker 
genes, and two samples showed amplification for only two marker genes. However, the 
amplification of any one of the three marker genes was considered to be a positive indication of 
the presence of pSK41 by McDougal et al. [59]. The reason for this inconsistency is not known. 
Also, traE and repA have been used to detect pSK41 plasmid previously [29]. Our results were 
consistent with their data as all the pSK41 plasmids from our study showed amplification for traE 
and repA genes.  
 
Prevalence of pSK41 among hVISA and non-hVISA isolates: In this study, 6.9% of 
hVISA isolates (8/84) and 3.33% of non-hVISA isolates (2/60) were found to carry pSK41. The 
pSK41 plasmid was found to be a low-prevalence plasmid in both populations. The overall 
prevalence of pSK41 in hVISA isolates compared to non-hVISA isolates was not statistica l ly 
significant (p=0.20). Controlling for age group, source of infection and year of infection via a 
matched analysis, we found that the results of matched analysis were not different from the overall 
results. Another study has reported a low (3%) prevalence of pSK41 in S. aureus [29]. This study 
looked for the presence of vancomycin resistance precursors in patients in Michigan with lower 
extremity wounds. Our results were consistent with Tosh et al findings.  
Although the prevalence of pSK41 was not statistically significant, the presence of pSK41 
cannot be overlooked because of its critical role in the transfer of vancomycin resistance. Previous 
studies have shown that pSK41 facilitates the transfer of vanA, a vancomycin resistance 
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determinant, carried by Tn1546 in association with an Inc-18 like plasmid, from VRE to S. aureus 
[27, 72]. Out of thirteen VRSA cases reported in the U.S., eight VRE strains associated with VRSA 
cases showed the presence of vanA operon on Inc-18-like plasmid [73] and seven of the recipient 
MRSA were found to contain pSK41 [27]. It was also shown that pSK41 can facilitate this transfer 
via a helper cell or even in a cell-free filtrate [52]. However, the presence of pSK41 appears to be 
essential for this discussed conjugation [52]. One study has recently reported a case of VRSA in 
Brazil that lacked the presence of pSK41-like plasmid. Instead, this isolate carried the plasmid 
pBRZ01. However, as reported in earlier studies, pSK41 need not be present in the recipient 
MRSA cell, it can facilitate the conjugation of Inc-18-like plasmid through a helper cell as well 
[52, 62]. Resemblance between pSK41 and pBRZ01 has not been reported to date.  
Despite being a low prevalence plasmid, pSK41 remains strongly associated with the 
emergence of VRSA cases. By having an infection with S. aureus containing pSK41 plasmid, 
patients may be at risk of developing a VRSA infection. Moreover, owing to reduced susceptibility 
towards vancomycin in hVISA, these patients receive longer treatments of vancomycin and stay 
in hospitals for a relatively long time, therefore, increasing the chance of VRE exposure and 
transfer of a vanA gene. Such patients have infections that are completely resistant to vancomycin 
and are left with very few options for treatment. Due to all these reasons, the incidence of pSK41 
cannot be overlooked.  
 
Prevalence of pSK41 in hVISA by patient severity: Only two of six patients infected 
with hVISA and carrying pSK41 were admitted to the ICU. Only the hVISA-infected patients were 
chosen to compare this prevalence. hVISA-infected patients do not respond effectively to 
vancomycin. Additionally, the presence of the multi-resistant plasmid, pSK41, was associated with 
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a reduction in cure rate as it confers resistance to many drugs, such as gentamycin, kanamycin, 
tobramycin, neomycin, and bleomycin [73]. Patients infected with pSK41-positive hVISA who 
are at a high level of clinical severity have very few options for treatment. 
In our study, the prevalence of pSK41 in hVISA by patient severity was not statistica l ly 
significant (p=0.99), which suggests that the presence of pSK41 is not necessarily associated with 
ICU admission. However, our data were not sufficient to generalize these results, and more work 
is needed. Little has been documented about the association of pSK41 with overall patient severity.  
 
Prevalence of pSK41 by spa type: The most common spa types among all the isolates 
were t002 (25%) and t008 (24.3%). These spa types have been associated with hospital associated-
MRSA and community associated-MRSA [74]. They are also the most common spa types in the 
U.S. [74]. Our results were consistent with these findings.  
The overall distribution of pSK41-positive samples was not specifically related to any spa 
type. Two isolates carried pSK41, in spa types t008, t004, and t062. One pSK41-positive isolate 
was detected in type t002 and one in type t3234. However, these results were in slight contrast 
with the results of spa types of 13 VRSA cases found in the U.S, in which nine of the thirteen 
VRSA isolates were spa type t002 [34]. Of the nine isolates, five carried pSK41, and four isolates 
did not carry pSK41 [34]. We did not find a high prevalence of t002 in pSK41-positive isolates; 
only one isolate carrying pSK41 was spa type t002. 
This association between the presence of pSK41 and the spa type has not been documented 
previously. We found that strains of S. aureus can carry this plasmid irrespective of strain type. 
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CHAPTER 5 
CONCLUSION 
From this study, it can be concluded that the multi-resistant plasmid, pSK41, is found at a 
low prevalence in hVISA isolates, and non-hVISA isolates recovered from patients with 
bloodstream infection. Even though the number was not sufficient to generate statistica l ly 
significant data, 6.9% of the total isolates in the study carried pSK41. This number cannot be 
ignored as it might indicate future development of VRSA.  
Secondly, pSK41 can be found in patients that are at high and low clinical severity. 
However, more work is needed to produce robust data regarding this association.  
Lastly, we can also conclude that the presence of pSK41 can be found in many spa types. 
The pSK41 plasmid does not appear to be associated with any particular spa type. 
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CHAPTER 6 
FUTURE EXPERIMENTS 
Future directions may include a comparative study of the clinical characteristics and 
outcomes of pSK41-positive and pSK41-negative isolates. A risk analysis would be performed to 
understand which population may be at risk of carrying pSK41-positive S. aureus infection, and 
also, to understand whether patients with pSK41 are unique in their clinical outcomes. 
Only thirteen cases of VRSA have been reported in the United States to date. Although 
pSK41 has been found at a low prevalence, its prevalence is still more than the incidence of VRSA 
cases in the United States. In future, the role of other possible barriers in the prevention of VRSA 
development might be studied. 
Eight out of thirteen VRSA cases were reported in Michigan. Therefore, studying the 
prevalence of pSK41 in patients from Michigan and comparing it with the patients from other 
states in USA is needed. More knowledge as to the prevalence in Michigan, compared to other 
states would inform current hypotheses on the mechanism of VRSA emergence.  
We also plan to study the prevalence of pSK41 by infection source, to understand if any 
particular infection is associated with detection of the pSK41 plasmid.  
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ABSTRACT 
COMPARATIVE STUDY OF THE PREVALENCE OF PSK41 IN HETEROGENOUS 
VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS ISOLATES 
AGAINST NON- HETEROGENOUS VANCOMYCIN-INTERMEDIATE 
STAPHYLOCOCCUS AUREUS ISOLATES AND THE PREVALENCE BY PATIENT 
SEVERITY 
by 
POORVA DIVEKAR 
December 2014 
Advisor: Dr. Emily T. Martin 
Major: Pharmaceutical Sciences  
Degree: Master of Science  
Earlier studies have reported that pSK41 plays an important role in the transfer of 
vancomycin resistance from Vancomycin-resistant Enterococci (VRE) to S. aureus. This transfer 
leads to the development of Vancomycin-resistant S. aureus (VRSA). Thirteen VRSA cases have 
been reported in the United States since 2002. To determine and compare the prevalence of pSK41 
in hVISA isolates against non-hVISA isolates and the comparison of the prevalence of pSK41 by 
patient severity and spa type.   
Samples were collected from patients presenting for the care of blood stream infect ion. 
Collection was done in Michigan, New York, Pennsylvania and Ohio. DNA was extracted from 
all the samples and checked for the presence of pSK41 using pSK41 marker genes. After 
confirming the final number of pSK41-positive isolates, the prevalence of pSK41 was compared 
between hVISA isolates and non-hVISA isolates. Secondly, the prevalence of pSK41 was 
compared by patient severity. Lastly, the distribution of pSK41 isolates among various spa types 
was studied by performing spa typing.   
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Out of 144 samples, 10 (6.9%) samples were found to contain pSK41. Eight pSK41-
positive isolates were hVISA and two were non-hVISA. The pSK41 plasmid was found to be a 
low-prevalence plasmid in both hVISA, and non-hVISA isolates. There was no significant 
association between the presence of pSK41 and patient severity.  Also, the presence was pSK41 
was observed in many spa types.  
The pSK41 plasmid is found at a low prevalence in hVISA isolates, and non-hVISA 
isolates recovered from patients with bloodstream infection. Even though a low prevalence of this 
plasmid was observed, 6.9% of the total isolates in the study carried pSK41. This number can’t be 
ignored as it might indicate future development of VRSA. Secondly, pSK41 can be found in 
patients that are at high and low clinical severity. However, more work is needed to produce robust 
data regarding this association. Lastly, we can also conclude that the presence of pSK41 can be 
found in many spa types. The pSK41 plasmid does not appear to be associated with any particular 
spa type.  
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